Special Issues

Mechanism of Action Magnifier – 2016 Desk Reference

Blinatumomab: a Bispecific CD19-Directed CD3 T-Cell Engager


Blinatumomab (derived from “B-lineage–specific antitumor mouse monoclonal antibody”) is a bispecific CD19-directed CD3 T-cell engaging antibody that binds to1-3: CD19 (expressed on the surface of cells of B-lineage origin) CD3 (expressed on the surface of T cells). More than 90% [ Read More ]

Lenvatinib: a Receptor Tyrosine Kinase Inhibitor

MOA Magnifiers

Lenvatinib (Figure) is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors1: VEGFR1 (FLT1) VEGFR2 (KDR) VEGFR3 (FLT4). Lenvatinib also inhibits other [ Read More ]